NASDAQ:DRUG Bright Minds Biosciences Q2 2025 Earnings Results & Report $52.63 +1.27 (+2.47%) As of 11:02 AM Eastern This is a fair market value price provided by Massive. Learn more. Bright Minds Biosciences beat analyst earnings expectations in its Q2 2025 results, released May 15, 2025. The company reported EPS of -$0.29 versus the -$0.39 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2025Report DateMay 15, 2025TimeBefore Market OpensConference Call DateMay 16, 2025Conference Call4:00 PM ET Bright Minds Biosciences EPS ResultsActual EPS-$0.29Consensus EPS -$0.39Beat/MissBeat by +$0.10One Year Ago EPSN/AEPS Beat Rate6 of last 6 quartersBright Minds Biosciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsBright Minds Biosciences' Q4 2026 earnings is estimated for Tuesday, December 22, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, December 23, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesEarnings HistoryCompany Profile Bright Minds Biosciences Q2 2025 Earnings FAQ Did Bright Minds Biosciences beat earnings estimates for Q2 2025? Bright Minds Biosciences (NASDAQ:DRUG) reported earnings of -$0.29 per share for Q2 2025, beating the consensus estimate of -$0.39. The report was announced on Thursday, May 15, 2025. When is Bright Minds Biosciences' next earnings date? Bright Minds Biosciences' next earnings date is estimated for Tuesday, December 22, 2026. MarketBeat tracks confirmed and estimated earnings dates for Bright Minds Biosciences on the company's earnings history page. Bright Minds Biosciences Earnings HeadlinesBright Minds Biosciences And 2 More Canadian Biotech StocksOctober 8, 2026 | finance.yahoo.comBright Minds Biosciences (DRUG) Receives a Buy from Piper SandlerOctober 7, 2026 | theglobeandmail.comThe Iran War Isn’t Chaos. It’s Strategy.Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congressmen no cameras, no staff. What he found afterward points to a coordinated Two-Front Economic War already in motion, according to his research at Behind the Markets.October 14 at 1:00 AM | Behind the Markets (Ad)Bright Minds Biosciences (NASDAQ:DRUG) Stock Moved Down to Sell by Wall Street ZenOctober 3, 2026 | americanbankingnews.comBright Minds Biosciences to Participate in the 2026 FPWR Research Symposium and PWS Family ConferenceSeptember 30, 2026 | globenewswire.comBright Minds Biosciences (DRUG) Receives a Rating Update from a Top AnalystSeptember 24, 2026 | theglobeandmail.comSee More Bright Minds Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Bright Minds Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bright Minds Biosciences and other key companies, straight to your email. Email Address About Bright Minds BiosciencesBright Minds Biosciences (NASDAQ:DRUG) is a biotechnology company focused on developing next-generation therapeutics for neuropsychiatric and neurological disorders. The company’s research is centered on selective serotonin receptor agonists designed to address conditions involving disrupted brain signaling while potentially avoiding some of the adverse effects associated with older serotonergic medicines. Bright Minds’ lead product candidate is BMB-101, a selective 5-HT2C receptor agonist being developed for disorders including epilepsy and other conditions involving neuronal hyperexcitability. The company has also pursued additional compounds targeting neuropsychiatric indications such as substance-use disorders, obesity and binge-eating disorder. Its development programs are intended to advance through clinical testing and, if successful, regulatory review. Bright Minds Biosciences is based in Vancouver, British Columbia, Canada, and conducts research and drug-development activities through its biotechnology operations. The company’s shares trade on the Nasdaq Capital Market under the symbol DRUG.View Bright Minds Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American BusinessTax Credit Turmoil: Why Enphase and SolarEdge Face a Tough RoadSurgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?Venezuela's Oil Revival Is Gaining Momentum—3 Energy Stocks Positioned to Benefit Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
